LRP4 and myasthenia gravis: In MG, autoantibodies against AChR, MuSK, and LRP4 disrupt the development of miniature end-plate potential (MEPP) and endplate potential (EPP) in the neuromuscular junction essential for the development of myofiber action potential required for effective muscle contraction [5, 64].